NicOx.... in attesa di.....

[elfrancese]

mon idee, c'est que le flottant est en realité composé non pas d'actionnaires individuels mais d'une multitudes de fond sous 2%, et ca prépare une prochaine offre à une somme dérisoire qui sera recu par le conseil d'administration, peut etre meme avant les résultats mont blanc vers 3 euro pourquoi pas
j'ai comme toi l'idée, que que quelque chose se prépare vu la force de certains echanges jeudi et vendredi comme le 28 mars ou j'ai vu 200k tournér en 20 minutes a la mi journée

 

[Jazalde]

Se c'è questa manipolazione c'è solo un motivo,se la vogliono prendere pagando due spicci,penso non più di 3 o 4 euro ed è chiaro che questi banditi possono farlo tranquillamente senza se e ma .....quindi volenti o non volenti il managemrnt di nicox verrà messo con le spalle al muro, questo se c'è la manipolazione come dite e di certo non è positivo per gli azionisti piccoli.

 

[Jazalde]

Vai Macron.
Al ballottagio credo vince di sicuro,e' un bel giorno,tra tante news negative.....

 

[elfrancese]

sondages du soir

MACRON 51 % - 49 % Marine

les 2 semaines vont être passionnantes !

 

[viralic]

Press Release

Nicox’s NCX 470 Dolomites Phase 2 Results Published in Journal of Glaucoma

April 11, 2022 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that the results from its Dolomites Phase 2 clinical trial of NCX 470 in patients with open-angle glaucoma or ocular hypertension have been published online by the Journal of Glaucoma, the official journal of the World Glaucoma Association. The publication “A Randomized, Controlled Comparison of NCX 470 (0.021%, 0.042% and 0.065%) and Latanoprost 0.005% in Patients with Open-Angle Glaucoma or Ocular Hypertension: The Dolomites Study”» is available by clicking here. NCX 470 is currently in two Phase 3 clinical trials. Dolomites was a dose-response Phase 2 clinical trial comparing three concentrations of NCX 470 ophthalmic solution (0.021%, 0.042%, and 0.065%) to latanoprost ophthalmic solution, 0.005% in 433 patients with open-angle glaucoma or ocular hypertension. Aligned with previously reported topline results on Dolomites, NCX 470 0.065% achieved statistical superiority compared to latanoprost 0.005% at all time-matched points measured on day 28, with a peak improvement in intraocular pressure (IOP) lowering of 1.4 mmHg greater than latanoprost. All tested concentrations of NCX 470 were statistically non-inferior to latanoprost and the dose response of NCX 470 showed improved IOP lowering with each incremental concentration. NCX 470 was safe and well-tolerated with no drug-related serious adverse events and no evidence of treatment-related systemic side effects. “As presented at the American Glaucoma Society in February 2020 by Dr David Wirta, the Dolomites Phase 2 data demonstrate that NCX 470, a monotherapy with a dual mechanism of action, has the potential to be a new standard of care for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.” said Doug Hubatsch, Chief Scientific Officer of Nicox. “We are pleased to be able to share the results of this Phase 2 trial in a peer-reviewed publication with the international glaucoma community. We are looking forward to the results of the subsequent Phase 3 trials of NCX 470 – Mont Blanc and Denali – which use a higher dose of NCX 470, based on the results of an initial adaptive design dose-ranging phase of the Mont Blanc trial.” NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once-daily dosed NCX 470 ophthalmic solution 0.1% over latanoprost ophthalmic solution 0.005% (first marketed as Xalatan), the most prescribed prostaglandin analog in the U.S. for patients with open-angle glaucoma or ocular hypertension.

About NCX 470

NCX 470 is a novel, potential best-in-class, nitric oxide (NO)-donating prostaglandin analog in development to reduce intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Glaucoma is a group of ocular diseases in which the optic nerve is injured, leading to peripheral and, ultimately, central visual field loss and it can eventually lead to blindness if not treated. It is frequently linked to abnormally high IOP (~90% of patients) due to blockage or malfunction of the eye’s aqueous humor drainage system in the front of the eye. In 2020, worldwide sales of treatments targeting glaucoma were over $6.0 billion out of a $24.3 billion worldwide market for ophthalmic drugs. NCX 470 is designed to release both bimatoprost and NO following instillation into the eye. Bimatoprost, marketed under the brand name LUMIGAN® by Allergan, Inc., is one of the leading products in the class of prostaglandin analogs, the most widely used class of drugs for IOP-lowering in patients with open-angle glaucoma or ocular hypertension.

 

[PIZZODIGINO]

Si vola !!!!!
Penso che la notizia della scoperta ufficiale dei manipolatori del corso dell'azione, abbia avuto un grande effetto.
Forse ora non assisteremo più a certe porcate.

 

[viralic]

Si vola !!!!!
Penso che la notizia della scoperta ufficiale dei manipolatori del corso dell'azione, abbia avuto un grande effetto.
Forse ora non assisteremo più a certe porcate.

lo penso anch'io....anche se tardi l AMF si è accorta e sanzionato quelle merde....da ora in avanti dovranno stare più attenti a fare certe porcate.

 

[Jazalde]

speriamo che sia solo questa la causa del ribasso.
il tempo sara' il giudice supremo.

 

[Jazalde]

Pura illusione i giochi continuano come sempre.

 

[elfrancese]

Je pense que l’illusion ce sont toutes ces ventes ridicules à un cours aussi bas !